Celgene’s Otezla Shines, On Track To Be A Fourth Blockbuster Pillar
Executive Summary
Sales of the psoriasis drug increased 170% in the second quarter to $242m, giving the blood cancer specialist a strong anchor as it looks to expand in inflammation and immunology.
You may also be interested in...
VC Roundup: Cleave Raises $37m To Maintain Phase I Momentum, Plus $233.5m In Recent Financings
Cleave Biosciences leads off a recent slate of venture capital financings with $37m to fund ongoing Phase I programs for the lead drug from its protein homeostasis-focused platform.
Celgene’s Otezla Gets Preliminary Nod From NICE At Second Attempt
Celgene’s near-blockbuster oral psoriasis drug Otezla is cleared by NICE in a second draft guidance for use in severe psoriasis, after the company comes up with an acceptable patient access scheme.
Blow For Celgene As Revlimid Trial Miss Removes Blockbuster Indication
Celgene Corp.'s hopes of extending the market reach of its blockbuster oncology therapy Revlimid (lenalidomide) have taken a blow as Phase III data for the drug in elderly diffuse large B-cell lymphoma (DLBCL) patients have failed to show benefit on overall survival.